120 related articles for article (PubMed ID: 31129650)
1. Screening of chemical libraries in pursuit of kallikrein-5 specific inhibitors for the treatment of inflammatory dermatoses.
Di Paolo CT; Filippou PS; Yu Y; Poda G; Diamandis EP; Prassas I
Clin Chem Lab Med; 2019 Oct; 57(11):1737-1743. PubMed ID: 31129650
[TBL] [Abstract][Full Text] [Related]
2. A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton Syndrome.
Liddle J; Beneton V; Benson M; Bingham R; Bouillot A; Boullay AB; Brook E; Cryan J; Denis A; Edgar E; Ferrie A; Fouchet MH; Grillot D; Holmes DS; Howes A; Krysa G; Laroze A; Lennon M; McClure F; Moquette A; Nicodeme E; Santiago B; Santos L; Smith KJ; Thorpe JH; Thripp G; Trottet L; Walker AL; Ward SA; Wang Y; Wilson S; Pearce AC; Hovnanian A
J Invest Dermatol; 2021 Sep; 141(9):2272-2279. PubMed ID: 33744298
[TBL] [Abstract][Full Text] [Related]
3. Persistent kallikrein 5 activation induces atopic dermatitis-like skin architecture independent of PAR2 activity.
Zhu Y; Underwood J; Macmillan D; Shariff L; O'Shaughnessy R; Harper JI; Pickard C; Friedmann PS; Healy E; Di WL
J Allergy Clin Immunol; 2017 Nov; 140(5):1310-1322.e5. PubMed ID: 28238749
[TBL] [Abstract][Full Text] [Related]
4. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation.
Borgoño CA; Michael IP; Komatsu N; Jayakumar A; Kapadia R; Clayman GL; Sotiropoulou G; Diamandis EP
J Biol Chem; 2007 Feb; 282(6):3640-52. PubMed ID: 17158887
[TBL] [Abstract][Full Text] [Related]
5. Kallikrein-related peptidase 14 is the second KLK protease targeted by the serpin vaspin.
Ulbricht D; Tindall CA; Oertwig K; Hanke S; Sträter N; Heiker JT
Biol Chem; 2018 Sep; 399(9):1079-1084. PubMed ID: 29494334
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Human Kallikrein 5 Protease by Triterpenoids from Natural Sources.
Matsubara Y; Matsumoto T; Koseki J; Kaneko A; Aiba S; Yamasaki K
Molecules; 2017 Oct; 22(11):. PubMed ID: 29077044
[TBL] [Abstract][Full Text] [Related]
7. Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis.
Chavarria-Smith J; Chiu CPC; Jackman JK; Yin J; Zhang J; Hackney JA; Lin WY; Tyagi T; Sun Y; Tao J; Dunlap D; Morton WD; Ghodge SV; Maun HR; Li H; Hernandez-Barry H; Loyet KM; Chen E; Liu J; Tam C; Yaspan BL; Cai H; Balazs M; Arron JR; Li J; Wittwer AJ; Pappu R; Austin CD; Lee WP; Lazarus RA; Sudhamsu J; Koerber JT; Yi T
Sci Transl Med; 2022 Dec; 14(675):eabp9159. PubMed ID: 36516271
[TBL] [Abstract][Full Text] [Related]
8. Tissue Kallikrein Inhibitors Based on the Sunflower Trypsin Inhibitor Scaffold - A Potential Therapeutic Intervention for Skin Diseases.
Chen W; Kinsler VA; Macmillan D; Di WL
PLoS One; 2016; 11(11):e0166268. PubMed ID: 27824929
[TBL] [Abstract][Full Text] [Related]
9. KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome.
Furio L; Pampalakis G; Michael IP; Nagy A; Sotiropoulou G; Hovnanian A
PLoS Genet; 2015 Sep; 11(9):e1005389. PubMed ID: 26390218
[TBL] [Abstract][Full Text] [Related]
10. 3-Acyltetramic acids as a novel class of inhibitors for human kallikreins 5 and 7.
de Souza AS; Pacheco BDC; Pinheiro S; Muri EMF; Dias LRS; Lima CHS; Garrett R; de Moraes MBM; de Souza BEG; Puzer L
Bioorg Med Chem Lett; 2019 May; 29(9):1094-1098. PubMed ID: 30833107
[TBL] [Abstract][Full Text] [Related]
11. Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum.
de Veer SJ; Furio L; Swedberg JE; Munro CA; Brattsand M; Clements JA; Hovnanian A; Harris JM
J Invest Dermatol; 2017 Feb; 137(2):430-439. PubMed ID: 27697464
[TBL] [Abstract][Full Text] [Related]
12. Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors.
de Veer SJ; Swedberg JE; Brattsand M; Clements JA; Harris JM
Biol Chem; 2016 Dec; 397(12):1237-1249. PubMed ID: 26894578
[TBL] [Abstract][Full Text] [Related]
13. Biological evaluation and docking studies of natural isocoumarins as inhibitors for human kallikrein 5 and 7.
Teixeira TS; Freitas RF; Abrahão O; Devienne KF; de Souza LR; Blaber SI; Blaber M; Kondo MY; Juliano MA; Juliano L; Puzer L
Bioorg Med Chem Lett; 2011 Oct; 21(20):6112-5. PubMed ID: 21903387
[TBL] [Abstract][Full Text] [Related]
14. Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases.
Stefansson K; Brattsand M; Roosterman D; Kempkes C; Bocheva G; Steinhoff M; Egelrud T
J Invest Dermatol; 2008 Jan; 128(1):18-25. PubMed ID: 17625593
[TBL] [Abstract][Full Text] [Related]
15. Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome.
White GV; Edgar EV; Holmes DS; Lewell XQ; Liddle J; Polyakova O; Smith KJ; Thorpe JH; Walker AL; Wang Y; Young RJ; Hovnanian A
Bioorg Med Chem Lett; 2019 Mar; 29(6):821-825. PubMed ID: 30691925
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, biological evaluation and molecular modeling of pseudo-peptides based statine as inhibitors for human tissue kallikrein 5.
Hoelz LVB; Zorzanelli BC; Azevedo PHRA; Passos SG; de Souza LR; Zani M; Pinheiro S; Puzer L; Dias LRS; Muri EMF
Eur J Med Chem; 2016 Apr; 112():39-47. PubMed ID: 26874743
[TBL] [Abstract][Full Text] [Related]
17. Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome.
Furio L; de Veer S; Jaillet M; Briot A; Robin A; Deraison C; Hovnanian A
J Exp Med; 2014 Mar; 211(3):499-513. PubMed ID: 24534191
[TBL] [Abstract][Full Text] [Related]
18. Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome.
Walker AL; Bingham RP; Edgar EV; Ferrie A; Holmes DS; Liddle J; Polyakova O; Rella M; Smith KJ; Thorpe JH; Wang Y; White GV; Young RJ; Hovnanian A
Bioorg Med Chem Lett; 2019 Jun; 29(12):1454-1458. PubMed ID: 31005442
[TBL] [Abstract][Full Text] [Related]
19. Antioxidant, antibacterial, and anti-inflammatory activities of standardized brazilin-rich Caesalpinia sappan extract.
Nirmal NP; Panichayupakaranant P
Pharm Biol; 2015; 53(9):1339-43. PubMed ID: 25864864
[TBL] [Abstract][Full Text] [Related]
20. Isomannide-based peptidomimetics as inhibitors for human tissue kallikreins 5 and 7.
Oliveira JP; Freitas RF; Melo LS; Barros TG; Santos JA; Juliano MA; Pinheiro S; Blaber M; Juliano L; Muri EM; Puzer L
ACS Med Chem Lett; 2014 Feb; 5(2):128-32. PubMed ID: 24900785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
